Due to safety concerns, Aristea Therapeutics announced Friday it is discontinuing the development of its Phase II lead program RIST4721. As a result, the San Diego-based biotech is also dissolving its business.
https://www.pharmalive.com/wp-content/uploads/2023/02/BioSpaceAristea2-13-2023.jpg350625BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2023-02-13 10:14:512023-02-13 10:14:51AstraZeneca spin-off Aristea folds after safety issues end lead program
